secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALISADE BIO, INC. (PALI)
CIK:        0001357459
Form:       8-K
Filed at:   2022-11-23T23:59:59+00:00
Accession:  0001493152-22-033543
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palisade Bio appoints Dr. Herbert Slade as Chief Medical Officer effective Nov 17, 2022
--------------------------------------------------------------------------------

- Dr. Slade will serve as part-time consultant CMO with annual compensation of $240,000.
- He had been consulting for the company since May 2022 and previously served as clinical advisor for LB1148.
- Over 25 years of pharmaceutical/medical device leadership; previously CMO at Smith & Nephew, DFB Pharma, 3M Pharma.
- No severance or termination benefits are provided in the consulting arrangement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222033543/0001493152-22-033543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357459/000149315222033543/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-033543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer